Innate Pharma S.A - IPHA Company Short-Term Debt

Innate Pharma (IPHA) - corporate logo

Innate Pharma S.A. (IPHA) develops agents to stimulate the body's defenses against tumors. This price chart reflects a metric at the level of 0.00. Business viability is determined by compliance with stringent clinical trial standards and partnerships with corporate behemoths. Furthermore, the success of the therapy depends on the seamless transport of drugs from development centers to clinics to prevent the spoilage of valuable samples.

IPHA: innate-pharma.com Short-Term Debt 07/04/2022 - 10/29/2026

IPHA (Innate Pharma S.A): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart Innate Pharma|IPHA - Average Forecast Price
- market capitalization data:
Market Value Innate Pharma S.A.|IPHA - Total Company Value
- book capitalization data:
Net Assets per Single Share Innate Pharma|IPHA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio innate-pharma.com|IPHA - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio Innate Pharma S.A.|IPHA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Innate Pharma S.A.|IPHA - Aggregate Debt Obligations|Debts to Book Capitalization Innate Pharma S.A.|IPHA - Long-Term Debt Volume|Company Short-Term Debt Innate Pharma
Analysis of all company metrics:Innate Pharma IPHA
Finished products of innate-pharma.com

Innate Pharma S.A. (IPHA) leverages an academic approach and the prestige of European science to retain leading oncology researchers. This model requires stable funding, which is reflected in the company's short-term debt dynamics. This metric measures obligations with a maturity of up to one year, identifying the risk of cash flow gaps. Controlling these payments allows the company to balance liquidity and the cost of capital. An analysis of the company's short-term debt confirms the issuer's financial stability.

Competitor analysis for Innate Pharma S.A.

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|pyxisoncology.com - Company Short-Term Debts|CGEN (Compugen) - Short-Term Debt Volume|Company Short-Term Debt IOBT|Company Current Liabilities STRO|Company Short-Term Debt INKT (MiNK Therapeutics, Inc.)|Company Current Liabilities werewolftx.com HOWL|Company Current Liabilities IMMX (Immix Biopharma)|alxoncology.com - Company Short-Term Debts|Cue Biopharma (CUE) - Company Short-Term Debt|PDSB: Company Short-Term Indebtedness|Company Short-Term Debt SONN|Short-Term Debt MAIABiotech.com|Liminatus Pharma LLC - Company Current Liabilities|Short-Term Indebtedness Lava Tx (LVTX)|Company Current Liabilities NextCure Corp|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt